A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.

MLA

Bowlus, Christopher L., et al. “A Phase II, Randomized, Open-Label, 52-Week Study of Seladelpar in Patients with Primary Biliary Cholangitis.” Journal of Hepatology, vol. 77, no. 2, Aug. 2022, pp. 353–64. EBSCOhost, https://doi.org/10.1016/j.jhep.2022.02.033.

APA

Bowlus, C. L., Galambos, M. R., Aspinall, R. J., Hirschfield, G. M., Jones, D. E. J., Dörffel, Y., Gordon, S. C., Harrison, S. A., Kremer, A. E., Mayo, M. J., Thuluvath, P. J., Levy, C., Swain, M. G., Neff, G. W., Sheridan, D. A., Stanca, C. M., Berg, C. P., Goel, A., Shiffman, M. L., … McWherter, C. A. (2022). A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. Journal of Hepatology, 77(2), 353–364. https://doi.org/10.1016/j.jhep.2022.02.033

Chicago

Bowlus, Christopher L, Michael R Galambos, Richard J Aspinall, Gideon M Hirschfield, David E J Jones, Yvonne Dörffel, Stuart C Gordon, et al. 2022. “A Phase II, Randomized, Open-Label, 52-Week Study of Seladelpar in Patients with Primary Biliary Cholangitis.” Journal of Hepatology 77 (2): 353–64. doi:10.1016/j.jhep.2022.02.033.